Lemonade Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Lemonade Inc trades at $46.5 (market cap $3.63B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 7× Lemonade Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lemonade Inc for 27 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| LMND | RPRX | |
|---|---|---|
Market Cap | $3.63B | $25.27B |
Volume | 1,544,794 | 3,671,183 |
Sector | Financials | Health |
52-Week High | $96.57 | $63.96 |
52-Week Low | $43.91 | $35.44 |
Typical Hold Time | 27 Days | 1 Days |
Enterprise Value | $3.49B | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
LMND trades at $46.46, down 0.79% on the day, with a bearish technical signal and key resistance at $48. Revenue growth is strong, rising to $738 million in 2025, but the company remains unprofitable with a net margin of -22.43%. Recent news highlights expansion into new states and AI-driven efficiency gains, targeting EBITDA profitability by late 2026.
The outlook balances high growth potential against persistent losses. Analyst consensus is divided with a $67 price target suggesting upside, but execution risks and competitive pressures remain key concerns. The path to profitability is the critical catalyst for shareholder value.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →